Organigram Global Inc (OGI) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion
Gross Sales: Increased 79% year-over-year, surpassing $100 million for the first time in a quarter.
Net Revenue: Up 74% year-over-year to $65.6 million.
International Sales: Increased 177% to $6.1 million from $2.2 million in the prior-year period.
Adjusted Gross Margin: $21.9 million or 33%, compared to $11.6 million or 31% in the prior-year period.
Adjusted EBITDA: $4.9 million compared to negative $1 million in the prior-year period.
Net Income: $42.5 million compared to a net loss of $27.1 million in Q2 fiscal 2024.
Cash Position: Total cash of $83.4 million as of March 31, including both restricted and unrestricted cash.
SG&A Costs: Total SG&A costs were $22.4 million, a 10% increase versus the prior period last year.
Capital Expenditures: Planned investment of $8 million to $10 million in sustaining capital expenditures during fiscal 2025.
Warning! GuruFocus has detected 2 Warning Signs with OGI.
Release Date: May 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Organigram Global Inc (NASDAQ:OGI) reported a record-breaking quarter by revenue, with gross sales up 79% year-over-year, surpassing $100 million for the first time.
The company achieved a leading market share in Canada, particularly in the vape category with a 21.7% share, and maintained strong positions in flower and pre-rolls.
International sales increased by 177% year-over-year, driven by strong demand in markets like Germany and Australia.
The integration of the Motif acquisition is progressing well, with expected synergies now estimated at $15 million annually, up from the previous $10 million.
Organigram Global Inc (NASDAQ:OGI) is expanding its presence in the US hemp-derived THC beverage market, with products now distributed in 10 states and carried by major retailers.
Despite the record revenue, the company experienced negative cash flow this quarter, primarily due to working capital investments and the Collective Project acquisition.
Margins from the Motif acquisition were lower than the core business, impacting overall adjusted gross margin.
The company faces a fragmented and competitive market in Canada, with the top three LPs holding only 27% of total market share.
There is potential for price compression in international markets, as value flower is starting to appear in Germany.
The US hemp-derived THC beverage market is highly competitive, with many brands and the need for significant investment to drive growth and consumer adoption.
Q: Can you provide more details on your international growth outlook for 2025, especially regarding the EU-GMP certification and its impact on capacity allocation between international and domestic markets? A: Beena Goldenberg, CEO: We are balancing demands between domestic and international sales. International sales have higher margins due to the absence of excise taxes, but we aim to maintain our domestic market leadership. We anticipate price compression in international markets, so it's crucial to balance both. We are increasing capacity with projects like the LED upgrade, adding 14,000 kilos of capacity. We expect higher international sales in the latter half of the year, driven by demand in Germany and other markets.
Q: What are your expectations for EBITDA margins in the medium term, and what are the key drivers for margin improvement? A: Greg Guyatt, CFO: We have realized about $1.5 million of the $5 million in targeted synergies for this year, mainly in COGS. EBITDA growth will be driven by margin growth, targeting a 40% gross margin in the second half of fiscal 2026, and cost management. As revenue grows, SG&A is not expected to increase materially, allowing for better leverage on the P&L and improved EBITDA margins.
Q: Can you explain the negative cash flow this quarter and your cash flow expectations for the rest of the year? A: Greg Guyatt, CFO: The negative cash flow was mainly due to a $6 million investment in the Collective Project acquisition and intentional working capital investment to prepare for strong growth in Q3 and Q4. We expect to be cash flow positive for the full year, with significant cash flow improvements starting in the third quarter.
Q: What is your strategy for the US hemp-derived THC market, and when do you expect it to be accretive to margins? A: Beena Goldenberg, CEO: We are in the early stages of expanding the Collective Project brand in the US, focusing on building distribution and consumer awareness. We expect to expand distribution to more states and launch a direct-to-consumer website soon. While we are investing in growth, we anticipate the US market to become more accretive as we scale and gain consumer adoption.
Q: What drove the significant increase in international sales, and was it due to new customers or expanded orders from existing partners? A: Beena Goldenberg, CEO: The growth was driven by meeting increased demand from existing customers, not new ones. There is strong demand for high-quality Canadian cannabis, and once a cultivar is established in medical markets, it leads to repeat purchases. We expect further growth with the upcoming EU-GMP certification, which will streamline fulfillment and potentially increase pricing.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
19 minutes ago
- Associated Press
MediPharm Labs' Board Continues Value Destruction for Shareholders with Sale of Hope Facility
Complete Incompetence at the Board Level Results in Fire Sale of Treasured MediPharm Asset, the Hope Facility, to a Competitor Hope Facility was One of Canada's Best Cultivation Assets Before it was Acquired by MediPharm, Grossly Mismanaged, and Ultimately Shut Down in 2024 MediPharm Labs' Board is Pursuing its Worst Deal Yet: A Highly Dilutive NO CASH Sale of the Remaining Company Apollo has a Concrete and Achievable Plan to Drive MediPharm's Share Price from Nearly $0.06 to Over $1.00, Restoring Value to its Loyal Shareholders SHAREHOLDERS ARE URGED TO VOTE THEGOLDCARD 'FOR' APOLLO CAPITAL'S SIX DIRECTOR NOMINEES AND NOT VOTE MEDIPHARM's GREEN CARD TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation ('Apollo Capital'), one of MediPharm Labs' ('MediPharm') largest investors, warns MediPharm shareholders that the Company's current leadership is continuing its pursuit of value destructive M&A, with the ultimate goal of a non-cash dilutive sale of the entire company. A sale of the Company which would trigger over $5M in change of control and other payments to current management. 'It's a travesty for shareholders to have what is believed to be a $12M asset sold for just $4.5M, likely netting shareholders less than $4M after fees and expenses. Worse still, the acquirer will wisely use the facility to produce cannabis for export that will directly compete with MediPharm in Europe,' says Regan McGee of Apollo Capital. 'Yesterday's fire sale announcement makes it crystal clear that MediPharm's Board has no actual value creation strategy, just a desire to sell off MediPharm's assets at shareholders' expense to keep paying themselves at 500% above market norms. Is MediPharm pursuing growth facilities as a strategy or not? Is the Napanee facility the next fire sale we will see to a competitor?' questions Regan McGee of Apollo Capital. Apollo expects the scaling of MediPharm's Napanee facility to cost shareholders significantly more than what the buyer of the Hope Facility will spend to achieve real profitability. Apollo expects the scaling of MediPharm's Napanee facility to cost between $3 million and $5 million and take 12 to 18 months to generate revenue. Apollo notes MediPharm's management team does not have cultivation experience, which could result in millions of investment dollars needed before it provides a return, if ever. The Hope Facility, formerly known as CannaFarms, was built by the highly respected Laflamme family to be one of the first licensed facilities in Canada. As exceptional visionaries, the Laflamme family built a world-class facility at immense personal cost to service patients in need, including military veterans. After nearly a decade of strong operational success as a positive driver for the community, MediPharm leadership not only failed to realize the value of its acquisition, but handed its assets to a competitor for well below market value. This sale is a tragic outcome for MediPharm shareholders. CEO David Pidduck has sold off MediPharm's Hope. Apollo Capital asks: Apollo Capital has invested significant capital into MediPharm and nominated highly qualified director candidates who can drive the urgent change needed and propel share price over $1.00. For more information, see our strategic five-pillar plan at Apollo urges shareholders to save their investments and vote the GOLD CARD by June 13, 2025. Shareholders are urged to NOT sign or return the green proxy cards sent by the Company. Contacts For Shareholders: Carson Proxy North American Toll-Free Phone: 1-800-530-5189 Local or Text Message: 416-751-2066 (collect calls accepted) E: [email protected] For Media: [email protected] This solicitation is being made by and on behalf of the Concerned Shareholder, who, as of the date of this Circular, beneficially owns or controls, directly and indirectly through its wholly-owned subsidiary, Nobul Technologies Inc., 12,491,500 common shares of the Company ('Common Shares'), representing approximately 3% of the total Common Shares issued and outstanding, and not by the management of the Company ('Management'). Legal Disclosures Information in Support of Public Broadcast Exemption under Canadian Law In connection with the annual general and special meeting (the 'Annual Meeting') of shareholders of MediPharm, Apollo Capital has filed an amended and restated dissident information circular dated May 15, 2025 (the 'Circular'), as amended and supplemented by an addendum to the Circular subsequently filed by the Concerned Stakeholder dated June 4, 2025 (the 'Addendum' and together with the Circular, the 'Amended Circular'), each in compliance with applicable corporate and securities laws. The Concerned Stakeholder has provided in, or incorporated by reference into, this press release the disclosure required under section 9.2(4) of NI 51-102 – Continuous Disclosure Obligations ('NI 51-102') and the corresponding exemption under the Business Corporations Act (Ontario), and has filed the Amended Circular, available under MediPharm's profile on SEDAR+ at The Amended Circular contains disclosure prescribed by applicable corporate law and disclosure required under section 9.2(6) of NI 51-102 in respect of the Concerned Stakeholder's director nominees, in accordance with corporate and securities laws applicable to public broadcast solicitations. The Amended Circular is hereby incorporated by reference into this press release and is available under MediPharm's profile on SEDAR+ at The registered office of the Company is 151 John Street, Barrie, Ontario, Canada L4N 2L1. SHAREHOLDERS OF MEDIPHARM ARE URGED TO READ THE AMENDED CIRCULAR CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and shareholders are able to obtain free copies of the Amended Circular and any amendments or supplements thereto and further proxy circulars at no charge under MediPharm's profile on SEDAR+ at In addition, shareholders are also able to obtain free copies of the Amended Circular and other relevant documents by contacting the Concerned Stakeholder's proxy solicitor, Carson Proxy Advisors Ltd. ('Carson Proxy') at 1-800-530-5189, local (collect outside North America): 416-751-2066 or by email at [email protected]. Proxies may be revoked in accordance with subsection 110(4) of the Business Corporations Act (Ontario) by a registered shareholder of Company shares: (a) by completing and signing a valid proxy bearing a later date and returning it in accordance with the instructions contained in the accompanying form of proxy; (b) by depositing an instrument in writing executed by the shareholder or by the shareholder's attorney authorized in writing; (c) by transmitting by telephonic or electronic means a revocation that is signed by electronic signature in accordance with applicable law, as the case may be: (i) at the registered office of the Company at any time up to and including the last business day preceding the day the Annual Meeting or any adjournment or postponement of the Annual Meeting is to be held, or (ii) with the chair of the Annual Meeting on the day of the Annual Meeting or any adjournment or postponement of the Annual Meeting; or (d) in any other manner permitted by law. In addition, proxies may be revoked by a non-registered holder of Company shares at any time by written notice to the intermediary in accordance with the instructions given to the non-registered holder by its intermediary. It should be noted that revocation of proxies or voting instructions by a non-registered holder can take several days or even longer to complete and, accordingly, any such revocation should be completed well in advance of the deadline prescribed in the form of proxy or voting instruction form to ensure it is given effect in respect of the Annual Meeting. The costs incurred in the preparation and mailing of any circular or proxy solicitation by the Concerned Stakeholder and any other participants named herein will be borne directly and indirectly by Apollo Capital. However, to the extent permitted under applicable law, Apollo Capital intends to seek reimbursement from the Company of all expenses incurred in connection with the solicitation of proxies for the election of its director nominees at the Annual Meeting. This press release and any solicitation made by the Concerned Stakeholder is, or will be, as applicable, made by such parties, and not by or on behalf of the management of the Company. Proxies may be solicited by proxy circular, mail, telephone, email or other electronic means, as well as by newspaper or other media advertising and in person by managers, directors, officers and employees of the Concerned Stakeholder who will not be specifically remunerated therefor. In addition, the Concerned Stakeholder may solicit proxies by way of public broadcast, including press release, speech or publication and any other manner permitted under applicable Canadian laws, and may engage the services of one or more agents and authorize other persons to assist it in soliciting proxies on their behalf. Apollo Capital has entered into an agreement with Carson Proxy for solicitation and advisory services in connection with the solicitation of proxies by the Concerned Stakeholder for the Annual Meeting, for which Carson Proxy will receive a fee from Apollo Capital not to exceed $250,000, together with reimbursement for reasonable and out-of-pocket expenses. Apollo Capital has also engaged Gasthalter & Co. LP ('G&Co') to act as communications consultant to provide the Concerned Stakeholder with certain communications, public relations and related services, for which G&Co will receive, from Apollo Capital, a minimum fee of US$75,000 in addition to a performance fee of US$250,000 in the event that the Concerned Stakeholder's nominees make up a majority of the board of directors of MediPharm (the 'Board') following the Annual Meeting, plus excess fees, related costs and expenses. Anteris Advisors, LLC ('Anteris') has also been retained by Apollo Capital to act as strategic consultant to provide the Concerned Stakeholder with certain activism strategy, material creation and strategic communications services, for which Anteris will receive, from Apollo Capital, a minimum fee of US$100,000 in addition to a success fee of US$100,000 in the event that one or more of the Concerned Stakeholder's nominees are appointed or elected to the Board following the Annual Meeting or as a result of any settlement or arrangement, plus excess fees, related costs and expenses. No member of the Concerned Stakeholder nor any of their respective associates or affiliates has or has had any material interest, direct or indirect, in any transaction since the beginning of the Company's last completed financial year or in any proposed transaction that has materially affected or will or would materially affect the Company or any of the Company's affiliates. No member of the Concerned Stakeholder nor any of their respective associates or affiliates has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Annual Meeting, other than setting the number of directors and the election of directors to the Board. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward‐looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward‐looking, and the words 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' and similar expressions are generally intended to identify forward‐looking statements. These statements are based on current expectations of the Concerned Stakeholder and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. All forward-looking statements contained herein are made only as of the date hereof and the Concerned Stakeholder disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Concerned Stakeholder hereafter becomes aware, except as required by applicable law. Hashtags: #ShareholderActivism #CorporateGovernance #InvestorProtection #Investor Alert #Investor Fraud #FinancialRegulation #CorporateCrime #FinancialCrime #HomelandSecurity #DHS #OpioidCrisis #OpioidEpidemic #OpioidLitigation #OpioidVictims #BMO #DEA #ONDCP
Associated Press
19 minutes ago
- Associated Press
Empress Grants Stock Options and Equity Incentives
VANCOUVER, BC / ACCESS Newswire / June 6, 2025 / Empress Royalty Corp. (TSXV:EMPR)(OTCQX:EMPYF) ('Empress Royalty' or the 'Company') announces that the Board of Directors has approved the granting of 1,400,000 incentive stock options (the 'Options') to purchase an aggregate of 1,400,000 common shares (the 'CommonShares') of the Company to certain directors, officers, employees, and consultants of the Company. Each Option is exercisable into one Common Share at an exercise price of $0.68, being the closing market price of Empress' common shares on June 6, 2025. The Options will vest as to one-third on the date of grant, one-third one year from the date of grant, and one-third two years from the date of grant and will expire on June 6, 2030. All stock option grants will be governed by the Company's Stock Option Plan which was approved by the shareholders of the Company at its last annual meeting of shareholders held on June 26, 2024. In addition, the Board of Directors has also approved the granting of 1,750,000 restricted share units ('RSUs') and 650,000 deferred share units ('DSUs') to certain directors, officers and consultants of the Company. Each of the RSUs and DSUs will vest equally over two years, with the first vesting date occurring June 6, 2026. Upon vesting, each RSU and DSU represents the right to receive one common share in the capital of the Company in accordance with the Company's Equity Incentive Plan, which was last approved by the shareholders of the Company at its annual meeting of shareholders held on September 28, 2022. ABOUT EMPRESS ROYALTY CORP. Empress is a global royalty and streaming creation company providing investors with a diversified portfolio of gold and silver investments. Empress has built a portfolio of precious metal investments and is actively investing in mining companies with development and production stage projects who require additional non-dilutive capital. The Company has strategic partnerships with Endeavour Financial and Terra Capital which allow Empress to not only access global investment opportunities but also bring unique mining finance expertise, deal structuring and access to capital markets. Empress is looking forward to continuously creating value for its shareholders through the proven royalty and streaming models. ON BEHALF OF EMPRESS ROYALTY CORP. Per: Alexandra Woodyer Sherron, CEO and President For further information, please visit our website at or contact us by email at [email protected] or by phone at +1.604.331.2080. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. The information contained herein includes 'forward-looking statements' and 'forward looking information' as defined under applicable Canadian securities laws ('forward-looking statements'). Forward-looking statements and information can generally be identified by the use of terms such as 'may', 'will', 'should', 'expect', 'intend', 'estimate' ,"continue', 'believe', 'plans', 'anticipate' or similar terms. Forward-looking information and statements include, but are not limited to, statements with respect to the activities, events or developments that Empress Royalty Corp. ('Empress' or the 'Company') expects or anticipates will or may occur in the future, including those regarding future growth and ability to create new streams or royalties, the development and focus of the Company , its acquisition strategy, the plans and expectations of the operators of the projects underlying its interests, including the proposed advancement and expansion of such projects; the results of exploration, development and production activities of the operators of such projects; and the Company's expectations regarding future revenues. Forward-looking information and statements are based on the then current expectations, beliefs, assumptions, estimates and forecasts about Empress's business and the industry and markets in which it operates. Forward-looking information and statements are made based upon numerous assumptions and although the assumptions made by the Company in providing forward-looking information and statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate. Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Empress to differ materially from any projections of results, performances and achievements of Empress including, without limitation, any inability of the operators of the properties underlying the Company's royalty and stream interests to execute proposed plans for such properties or to achieve planned development and production estimates and goals, risks related to the operators of the projects in which the Company holds interests, including the successful continuation of operations at such projects by those operators, risks related to exploration, development, permitting, infrastructure, operating or technical difficulties on any such projects, risks related to international operations, government relations and environmental regulation, uncertainty relating to the availability and costs of financing needed in the future and the Company's ability to carry out its growth plans as well as the impact of the COVID-19 pandemic and other related risks and uncertainties. For a discussion of important factors which could cause actual results to differ from forward-looking statements, refer to the annual information form of Empress for the year ended December 31, 2024 and its other publicly filed documents under its profile at . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and statements, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information and statements. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws. Disclosure relating to properties in which Empress holds royalty or stream interests is based on information publicly disclosed by the owners or operators of such properties. The Company generally has limited or no access to the properties underlying its interests and is largely dependent on the disclosure of the operators of its interests and other publicly available information. The Company generally has limited or no ability to verify such information. Although the Company does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. In addition, certain information publicly reported by operators may relate to a larger property than the area covered by the Company's interest, which often may only apply to a portion of the overall project area or applicable mineral resources or reserves. SOURCE: Empress Royalty Corp. press release
Yahoo
an hour ago
- Yahoo
RBC Capital Reiterated an Outperform Rating on Lyft (LYFT), Assigning a $21 PT
On June 5, RBC Capital analysts maintained an Outperform rating on Lyft, Inc. (NASDAQ:LYFT) with a price target of $21. The analysts mentioned the current rationality in the ride-sharing space, observing identical pricing and pick-up windows for Lyft and Uber, its market rival. Lyft's revenue has demonstrated solid growth over the last year, coming in at 27%. A ridesharing passenger and driver in a car, looking out the window in anticipation of their destination. RBC reported that Lyft, Inc. (NASDAQ:LYFT) is a sector winner year-to-date, ranking fifth overall with an 18% increase, compared to the 1% boost in the Nasdaq. According to the analysts, this performance was driven by Lyft's limited tariff exposure and GenAI concerns, combined with strong execution. Another positive development commended by RBC was Lyft, Inc. (NASDAQ:LYFT)'s autonomous vehicle launch with May Mobility, which is on the horizon. However, the soon-to-be Tesla launch is a potential competitive risk, though analysts commented that a stock selloff related to Tesla was a buying opportunity. The analysts also highlighted Lyft's promising valuation at 7.3x its forecasted 2026 EBITDA. This valuation, paired with the company's tactical plans, was a factor that contributed to RBC's Outperform rating. Lyft, Inc. (NASDAQ:LYFT) is a leading peer-to-peer transportation company operating across the United States and Canada, offering ridesharing, shared bikes/scooters, and Express Drive rentals. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
